Supplemental Figure 1

Click here to download Supporting Document: Supp F 1 colitis parameters nocap.pdf



Supplementary Figure 1: Surrogate markers of colitis activity for comparator groups

Supplemental Figure 2

Click here to download Supporting Document: Supp F 2 Cytokines and Tcell markers.pdf



Supplementary Figure 2: Cytokine and T-cell profiles of WT and IDO1$^{-/-}$ mouse tumors.

Supplemental Figure 3
Click here to download Supporting Document: Supp F

SUPPLEMENTARY FIGURE 3



Supplementary Figure 3: IDO1 inhibitors L-1mT and D-1mT exert direct concentration dependent suppression of proliferation in two human colon cancer cell lines with constitutive and inducible IDO1 expression

Supplemental Figure 4

Click here to download Supporting Document: Supp F



Supplementary Figure 4: IDO1 expressing colon cancer cells have increased proliferation in response to kynurenine based tryptophan catabolites when IDO1 activity is blocked.

Supplementary Table 1
Click here to download Supporting Document: Supplementary Table 1.docx

Supplementary Table 1: qRT-PCR primers

Gene	Forward Primer	Reverse Primer
Mouse Ido1	CGG ACT GAG AGG ACA CAG GTT AC	ACA CAT ACG CCA TGG TGA TGT AC
Human IDO1	CAC TTT GCT AAA GGC GCT GTT GGA	GGT TGC CTT TCC AGC CAG ACA AAT
CD3e	ATG CGG TGG AAC ACT TTC TGG	GCA CGT CAA CTC TAC ACT GGT
FoxP3	CCC ATC CCC AGG AGT CTT G	ACC ATG ACT AGG GGC ACT GTA
IL17	CTC CAG AAG GCC CTC AGA CTA C	GGG TCT TCA TTG CGG TGG
GAPDH	TGC ACC ACC AAC TGC TTA G	GAT GCA GGG ATG ATG TTC
TNFα	GAC CCT CAG ACT CAG ATC ATC TTC T	CCA CTT GGT GGT TTG CTA CGA
IFNγ	AGG CCA TCA GCA ACA ACA TAA GCG	TGG GTT GTT GAC CTC AAA CTT GGC
IFNα	TGC TTT CCT GAT GAC CCT GCT AGT	ATC CCA AGC AGC AGA TGA GTC CTT
IL6	CCA GAA ACC GCT ATG AAG TTC CT	CAC CAG CAT CAG TCC CAA GA
IL10	CCC TTT GCT ATG GTG TCC TT	TGG TTT CTC TTC CCA AGA CC
TGFβ	AGT GTG ACC TGG AGT TTC GGA GAT	TTG CCC TGA GGA CTT TCT TGA CCT
IL1β	TCA GGC AGG CAG TAT CAC TCA	GGA AGG TCC ACG GGA AAG AC
Axin2	CAA CAC CAG GCG GAA CGA A	GCC CAA TAA GGA GTG TAA GGA CT

Supplementary Fig Legends
Click here to download Supporting Document: CAC Paper Supp Figure Legends 5-1-13.pdf

Supplementary Table 1: qRT-PCR primers

Supplementary Figure 1: Surrogate markers of colitis activity for comparator groups. A,B) Disease activity index (diarrhea + hematochezia). C-E) Colon length and final day stool score for comparator groups: WT vs IDO1$^{-/-}$, Placebo vs L-1mT, Rag$^{-/-}$ and Rag$^{-/-}$/IDO1$^{-/-}$ (DbKO) mice. (Final Stool scoring based on the following: 0-normal dry pellet; 1-moist formed pellet; 2-soft poorly formed stool; 3-diarrhea/stool present on fur) F) Colitis-associated cytokines from non-tumor distal colon tissue of WT vs IDO1$^{-/-}$ (n=8/group).

Supplementary Figure 2: Cytokine and T-cell profiles of WT and IDO1$^{-/-}$ mouse tumors. A) Profile of tumor cytokines relevant in colitis associated cancer compared to adjacent non-tumor tissue with all samples normalized to GAPDH. B) CD3 and FoxP3 mRNA expression in tumors relative to GAPDH. C) CD3e/FoxP3 ratio per individual tumor. n=6-8 mice/group ≥1 tumor/mouse. *P<.05 and **P<.01 for tumor vs non-tumor tissue. No significant difference between WT and IDO1$^{-/-}$ for any cytokine.

Supplementary Figure 3: IDO1 inhibitors L-1mT and D-1mT exert direct concentration dependent suppression of proliferation in two human colon cancer cell lines with constitutive and inducible IDO1 expression A) HCT 116 cells B) HT-29 cells. Tryptophan (as control) or 1mT added to media 24 hours after cell plating and allowed to incubate in culture x72 hours prior to MTT proliferation assay.

Supplementary Figure 4: IDO1 expressing colon cancer cells have increased proliferation in response to kynurenine based tryptophan catabolites when IDO1 activity is blocked. HCT 116 and HT-29 cells were treated with kynurenine metabolites in the setting of A) IDO1 blockade (500 mg L-1mT and siIDO) or B-C) constitutive IDO1 expression for a total of 48 hours. MTT incorporation assay was used to assess proliferation. *P<0.05, **P<0.01, ***P<0.001 vs IDO1 inhibition state. #P<0.05, ## P<0.01 vs control.

Supplementary Table 1: qRT-PCR primers

Supplementary Figure 1: Surrogate markers of colitis activity for comparator groups. A,B) Disease activity index (diarrhea + hematochezia). C-E) Colon length and final day stool score for comparator groups: WT vs IDO1$^{-/-}$, Placebo vs L-1mT, Rag$^{-/-}$ and Rag$^{-/-}$/IDO1$^{-/-}$ (DbKO) mice. (Final Stool scoring based on the following: 0-normal dry pellet; 1-moist formed pellet; 2-soft poorly formed stool; 3-diarrhea/stool present on fur) F) Colitis-associated cytokines from non-tumor distal colon tissue of WT vs IDO1$^{-/-}$ (n=8/group).

Supplementary Figure 2: Cytokine and T-cell profiles of WT and IDO1$^{-/-}$ mouse tumors. A) Profile of tumor cytokines relevant in colitis associated cancer compared to adjacent non-tumor tissue with all samples normalized to GAPDH. B) CD3 and FoxP3 mRNA expression in tumors relative to GAPDH. C) CD3e/FoxP3 ratio per individual tumor. n=6-8 mice/group ≥1 tumor/mouse. *P<.05 and **P<.01 for tumor vs non-tumor tissue. No significant difference between WT and IDO1$^{-/-}$ for any cytokine.

Supplementary Figure 3: IDO1 inhibitors L-1mT and D-1mT exert direct concentration dependent suppression of proliferation in two human colon cancer cell lines with constitutive and inducible IDO1 expression A) HCT 116 cells B) HT-29 cells. Tryptophan (as control) or 1mT added to media 24 hours after cell plating and allowed to incubate in culture x72 hours prior to MTT proliferation assay.

Supplementary Figure 4: IDO1 expressing colon cancer cells have increased proliferation in response to kynurenine based tryptophan catabolites when IDO1 activity is blocked. HCT 116 and HT-29 cells were treated with kynurenine metabolites in the setting of A) IDO1 blockade (500 mg L-1mT and siIDO) or B-C) constitutive IDO1 expression for a total of 48 hours. MTT incorporation assay was used to assess proliferation. *P<0.05, **P<0.01, ***P<0.001 vs IDO1 inhibition state. #P<0.05, ## P<0.01 vs control.